PND52 PAYER AND SOCIETAL BENEFIT OF PEGINTERFERON BETA-1A VERSUS SUBCUTANEOUS INTERFERON BETA-1A IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY
نویسندگان
چکیده
منابع مشابه
Cost-Effectiveness Analysis of Peginterferon Beta-1a In Italian Relapsing Remitting Multiple Sclerosis Management.
Milan, Italy Cost-Effectiveness Analysis of Peginterferon Beta-1a in Italian Relapsing-Remitting Multiple Sclerosis Management Iannazzo S,1 Santoni L,2 Saleri C,2 Puma E,2 Vestri G,2 Giuliani L,1 Canonico PL,3 Centonze D4 1SIHS Health Economics Consulting, Torino, Italy; 2Biogen Italia, Milan, Italy; 3Department of Pharmaceutical Sciences, University of Eastern Piedmont, Novara, Italy; 4Centre ...
متن کاملFingolimod versus High Dose Interferon Beta-1a in Multiple Sclerosis: A Randomized Clinical Trial
Background: High dose Interferon Beta and Fingolimod are efficient in Multiple Sclerosis. Objectives: Comparison the efficacy of these two drugs in patients with treatment failure on low dose interferon beta. Materials and Methods: The MS patients (McDonald criteria 2010) with the history of unbeneficial treatment on low dose interferon beta participated in this randomized clinical trial ...
متن کاملThe effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis
BACKGROUND Spinal cord atrophy occurs early in multiple sclerosis (MS) and impacts disability. The therapeutic effect of interferon beta-1a (IFNβ-1a) on spinal cord atrophy in patients with relapsing-remitting (RR) MS has not been explored. METHODS We retrospectively identified 16 consecutive patients receiving weekly intramuscular IFNβ-1a for 2 years [baseline age (mean ± SD) 47.7 ± 7.5 year...
متن کاملAcute Liver Dysfunction Associated With Interferon-Beta-1a (Avonex®) Use in A Young Female Patient with Relapsing-Remitting Multiple Sclerosis (RRMS)
Background: It has been reported that liver function alterations occur in 8–38% of patients with relapsing-remitting multiple sclerosis (RRMS) treated with interferon-beta in controlled clinical trials or in prospective but non-controlled studies. We report herein a case of symptomatic liver dysfunction associated with two-year-period of regular interferon-beta-1a (Avonex®) intramuscular inje...
متن کاملNatalizumab plus interferon beta-1a for relapsing multiple sclerosis.
BACKGROUND Interferon beta is used to modify the course of relapsing multiple sclerosis. Despite interferon beta therapy, many patients have relapses. Natalizumab, an alpha4 integrin antagonist, appeared to be safe and effective alone and when added to interferon beta-1a in preliminary studies. METHODS We randomly assigned 1171 patients who, despite interferon beta-1a therapy, had had at leas...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2019
ISSN: 1098-3015
DOI: 10.1016/j.jval.2019.09.1822